Spectral AI Announces 2023 Third Quarter Financial Results
Highlights Continuing Progress in Developing and Commercializing AI-Driven DeepView® System Wound Healing Assessment Technology Affirms Full Year Revenue Guidance for 2023…
Pharmaceuticals, Biotechnology and Life Sciences
Highlights Continuing Progress in Developing and Commercializing AI-Driven DeepView® System Wound Healing Assessment Technology Affirms Full Year Revenue Guidance for 2023…
TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a…
IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advanceRemediation strategies following…
Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic…
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing…
Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of…
ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with…
ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with…
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentationSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics,…
– Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML to be…